CN1621041A - 具有镇痛作用的药物组合物 - Google Patents
具有镇痛作用的药物组合物 Download PDFInfo
- Publication number
- CN1621041A CN1621041A CNA2004100404834A CN200410040483A CN1621041A CN 1621041 A CN1621041 A CN 1621041A CN A2004100404834 A CNA2004100404834 A CN A2004100404834A CN 200410040483 A CN200410040483 A CN 200410040483A CN 1621041 A CN1621041 A CN 1621041A
- Authority
- CN
- China
- Prior art keywords
- composition
- medicine
- pharmaceutical composition
- formula
- analgesic activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 16
- 208000002193 Pain Diseases 0.000 title description 22
- 230000036407 pain Effects 0.000 title description 21
- 239000003814 drug Substances 0.000 claims abstract description 82
- 239000000203 mixture Substances 0.000 claims abstract description 71
- 230000000202 analgesic effect Effects 0.000 claims abstract description 32
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940039750 aconitine Drugs 0.000 claims abstract description 6
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000006210 lotion Substances 0.000 claims abstract description 6
- -1 aconitine compound Chemical class 0.000 claims abstract description 3
- 239000002674 ointment Substances 0.000 claims abstract description 3
- 239000000829 suppository Substances 0.000 claims abstract description 3
- 229940079593 drug Drugs 0.000 claims description 47
- DPMGVDIWDTYPMP-UHFFFAOYSA-N Hypaconitine Natural products COCC12CCC(OC)C3(CN(C)C1)C4CC5(O)C(OC)C(O)C(CC(OC)C23)(OC(=O)C)C4C5OC(=O)c6ccccc6 DPMGVDIWDTYPMP-UHFFFAOYSA-N 0.000 claims description 14
- XUHJBXVYNBQQBD-UHFFFAOYSA-N mesaconitine Natural products COC1CC(O)C2(COC)CN(C)C3C(C(C45)(OC(C)=O)C(O)C6OC)C(OC)C2C31C4CC6(O)C5OC(=O)C1=CC=CC=C1 XUHJBXVYNBQQBD-UHFFFAOYSA-N 0.000 claims description 13
- XUHJBXVYNBQQBD-GQPWXMLZSA-N molport-002-525-145 Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@]45[C@@H]6[C@@H](OC)[C@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H]4N(C)C[C@@]6([C@@H](C[C@@H]5OC)O)COC)C(=O)C1=CC=CC=C1 XUHJBXVYNBQQBD-GQPWXMLZSA-N 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 9
- FIDOCHXHMJHKRW-GKVQVCCJSA-N hypaconitine Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@]45[C@@H](OC)CC[C@@]6([C@H]4[C@@H](OC)[C@H]([C@@](OC(C)=O)([C@H]31)[C@@H](O)[C@H]2OC)[C@H]5N(C)C6)COC)C(=O)C1=CC=CC=C1 FIDOCHXHMJHKRW-GKVQVCCJSA-N 0.000 claims description 9
- PULWZCUZNRVAHT-YESQXFQNSA-N benzoylmesaconitine Chemical compound O([C@H]1[C@@]2(O)C[C@@H]3C45[C@@H]6[C@@H](OC)C([C@@]([C@H]31)(O)[C@@H](O)[C@@H]2OC)C4N(C)C[C@@]6([C@@H](CC5OC)O)COC)C(=O)C1=CC=CC=C1 PULWZCUZNRVAHT-YESQXFQNSA-N 0.000 claims description 7
- 238000002347 injection Methods 0.000 abstract description 6
- 239000007924 injection Substances 0.000 abstract description 6
- 231100000053 low toxicity Toxicity 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 239000008187 granular material Substances 0.000 description 8
- 208000000114 Pain Threshold Diseases 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000037040 pain threshold Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 6
- 230000036592 analgesia Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 241000227129 Aconitum Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940040145 liniment Drugs 0.000 description 3
- 239000000865 liniment Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000011505 plaster Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 2
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229960000482 pethidine Drugs 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- NBUHTTJGQKIBMR-UHFFFAOYSA-N 4,6-dimethylpyrimidin-5-amine Chemical compound CC1=NC=NC(C)=C1N NBUHTTJGQKIBMR-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000205571 Caulophyllum Species 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical class [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- PULWZCUZNRVAHT-LOCDBSKESA-N benzoylmesaconine Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@]45[C@@H]6[C@@H](OC)[C@H]([C@@]([C@H]31)(O)[C@@H](O)[C@@H]2OC)[C@H]4N(C)C[C@@]6([C@@H](C[C@@H]5OC)O)COC)C(=O)C1=CC=CC=C1 PULWZCUZNRVAHT-LOCDBSKESA-N 0.000 description 1
- PULWZCUZNRVAHT-UHFFFAOYSA-N benzoylmesaconine Natural products COC1CC(O)C2(COC)CN(C)C3C(C(C45)(O)C(O)C6OC)C(OC)C2C31C4CC6(O)C5OC(=O)C1=CC=CC=C1 PULWZCUZNRVAHT-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- BCAARMUWIRURQS-UHFFFAOYSA-N dicalcium;oxocalcium;silicate Chemical compound [Ca+2].[Ca+2].[Ca]=O.[O-][Si]([O-])([O-])[O-] BCAARMUWIRURQS-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940051129 meperidine hydrochloride Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组 别 | 给药剂量(mg/kg) | 扭体数( X±SD) | 疼痛抑制率(%) |
空白对照组 | - | 39.3 | - |
对照药物A | 40 | 0±0*** | 100.00 |
对照药物B | 200 | 3.1±3.2*** | 92.11 |
式(II)成分 | 4 | 2.8 ±4.5*** | 92.88 |
2 | 23.6±10.9* | 39.95 | |
1 | 24.5±9.8* | 37.66 | |
0.5 | 27.6±11.5 | 29.77 | |
式(III)成分 | 2 | 19.3±10.0△△ | 50.89 |
1 | 21.8±12.6△△ | 44.53 | |
0.5 | 20.0 ±9.6△△ | 49.11 | |
0.25 | 33.6±11.5 | 14.50 | |
式(IV)成分 | 400 | 20.4±12.9▲▲ | 40.52 |
200 | 21.0±15.1▲ | 38.78 | |
100 | 27.4±15.9 | 20.12 | |
50 | 27.2±12.2 | 20.70 |
组 别 | 剂量(mg/kg) | 给药后痛阈提高率(%)( X±SD) | ||||
15分钟 | 30分钟 | 60分钟 | 90分钟 | 120分钟 | ||
空白对照 | - | 12.1±45.0 | -6.3±31.4 | -0.5±38.7 | -11.3±34.2 | 11.1±38.8 |
对照药A | 40 | 284.4±229.5** | 181.3±98.4*** | 118.9±117.5** | 44.7±64.4* | 0.7±48.3 |
式(II)成分 | 4 | 142.7±139.4* | 104.1±137.4* | 81.7±100.0* | 34.4±59.3* | 59.1±55.6* |
2 | 72.4±57.6* | 36.0±53.4 | 17.3±56.1 | 15.3±60.1 | -13.0±33.1 | |
1 | -166±31.9 | -31.9±24.2 | -18.1±34.5 | -13.0±14.9 | 28.3±56.3 | |
式(III)成分 | 100 | 124.8±165.4 | 97.7±184.6 | 64.3±149.5 | 108.3±105.0△△ | 49.0±52.9 |
50 | 21.4±42.9 | 14.4±34.7 | 7.9±37.8 | 30.4±44.1△ | 36.0±42.6 | |
25 | 39.7±76.6 | 59.2±146.9 | 37.2±88.5 | 61.3±82.1△ | 80.7±100.1 | |
12.5 | 12.1±45.0 | -6.3±31.4 | -0.5±38.7 | -11.3±34.2 | 11.1±38.8 | |
式(IV)成分 | 400 | 41.3±90.2 | 35.2±57.2▲ | 78.8±104.0▲ | 59.5±88.5 | 53.7±117.0 |
200 | 22.1±52.0 | 32.9±45.1▲ | 40.3±76.4 | 46.0±87.4 | 53.6±93.9 | |
100 | -0.4±33.8 | 13.7±52.3 | 64.6±76.7▲ | 71.1±104.5* | 106.2±116.5 |
例1 | 例2 | 例3 | 例4 | 例5 | 例6 | 例7 | |
中乌头碱 | 13 | 13 | 13 | - | 13 | - | - |
下乌头碱 | 12 | 12 | - | 12 | - | 12 | - |
苯甲酰中乌头原碱 | 60 | - | 60 | 60 | - | - | 60 |
淀粉(×1000) | 200 | 200 | 200 | 200 | 200 | 200 | 200 |
例15 | 例16 | 例17 | 例18 | 例19 | 例20 | 例21 | |
中乌头碱 | 8.9 | 8.9 | 8.9 | - | 8.9 | - | - |
下乌头碱 | 7.8 | 7.8 | - | 7.8 | - | 7.8 | - |
苯甲酰中乌头原碱 | 41.1 | - | 41.1 | 41.1 | - | - | 41.1 |
淀粉(×1000) | 800 | 800 | 800 | 800 | 800 | 800 | 800 |
糖粉(×1000) | 200 | 200 | 200 | 200 | 200 | 200 | 200 |
例15 | 例16 | 例17 | 例18 | 例19 | 例20 | 例21 | |
中乌头碱 | 8.9 | 8.9 | 8.9 | - | 8.9 | - | - |
下乌头碱 | 7.8 | 7.8 | - | 7.8 | - | 7.8 | - |
苯甲酰中乌头原碱 | 41.1 | - | 41.1 | 41.1 | - | - | 41.1 |
吐温-80(×1000) | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
EDTA(×1000) | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
注射用水(×1000) | 至1000 | 至1000 | 至1000 | 至1000 | 至1000 | 至1000 | 至1000 |
例15 | 例16 | 例17 | 例18 | 例19 | 例20 | 例21 | |
中乌头碱 | 89 | 89 | 89 | - | 89 | - | - |
下乌头碱 | 78 | 78 | - | 78 | - | 78 | - |
苯甲酰中乌头原碱 | 411 | - | 411 | 411 | - | - | 411 |
二氯二氟甲烷(×1000) | 7000 | 7000 | 7000 | 7000 | 7000 | 7000 | 7000 |
医用乙醇(×1000) | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 |
香味剂 | 适量 | 适量 | 适量 | 适量 | 适量 | 适量 | 适量 |
例36 | 例37 | 例38 | 例39 | 例40 | 例41 | 例42 | |
中乌头碱 | 65 | 65 | 65 | - | 65 | 65 | - |
下乌头碱 | 65 | 65 | - | 65 | - | - | - |
苯甲酰中乌头原碱 | 130 | - | 130 | 130 | - | - | 130 |
医用乙醇(×1000) | 200 | 200 | 200 | 200 | 200 | 200 | 200 |
纯化水(×1000) | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 |
Claims (10)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2004100404834A CN1621041A (zh) | 2004-08-19 | 2004-08-19 | 具有镇痛作用的药物组合物 |
PCT/CN2005/001295 WO2006017994A1 (fr) | 2004-08-19 | 2005-08-18 | Préparation pharmaceutique analgésique |
CN2005800199141A CN1968694B (zh) | 2004-08-19 | 2005-08-18 | 具有镇痛作用的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2004100404834A CN1621041A (zh) | 2004-08-19 | 2004-08-19 | 具有镇痛作用的药物组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1621041A true CN1621041A (zh) | 2005-06-01 |
Family
ID=34763624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2004100404834A Pending CN1621041A (zh) | 2004-08-19 | 2004-08-19 | 具有镇痛作用的药物组合物 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN1621041A (zh) |
WO (1) | WO2006017994A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111991392A (zh) * | 2020-09-10 | 2020-11-27 | 青岛大学附属医院 | 一种抗疱疹病毒感染的生物碱及其组合物与应用 |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7889747B2 (en) | 2006-05-31 | 2011-02-15 | Honeywell International Inc. | Apparatus, system, and method for integrating a wireless network with wired field devices in a process control system |
US7675935B2 (en) | 2006-05-31 | 2010-03-09 | Honeywell International Inc. | Apparatus and method for integrating wireless or other field devices in a process control system |
US7965664B2 (en) | 2006-05-31 | 2011-06-21 | Honeywell International Inc. | Apparatus and method for integrating wireless field devices with a wired protocol in a process control system |
US7876722B2 (en) | 2006-05-31 | 2011-01-25 | Honeywell International Inc. | System and method for wireless communication between wired field devices and control system components |
US8266602B2 (en) | 2006-05-31 | 2012-09-11 | Honeywell International Inc. | Apparatus and method for converting between device description languages in a process control system |
US8756412B2 (en) | 2010-04-16 | 2014-06-17 | Honeywell International Inc. | Gateway supporting transparent redundancy in process control systems and other systems and related method |
US8498201B2 (en) | 2010-08-26 | 2013-07-30 | Honeywell International Inc. | Apparatus and method for improving the reliability of industrial wireless networks that experience outages in backbone connectivity |
US8924498B2 (en) | 2010-11-09 | 2014-12-30 | Honeywell International Inc. | Method and system for process control network migration |
CN102832703B (zh) * | 2011-06-16 | 2016-06-01 | 国电南瑞科技股份有限公司 | 基于模型转换机的变电站与调度主站模型快速转换方法 |
US9239574B2 (en) | 2011-06-30 | 2016-01-19 | Honeywell International Inc. | Apparatus for automating field device operations by capturing device method execution steps for later use and related method |
US9191843B2 (en) | 2013-06-12 | 2015-11-17 | Honeywell International Inc. | Apparatus and method for measuring and reporting redundant wireless connectivity over time |
US9110838B2 (en) | 2013-07-31 | 2015-08-18 | Honeywell International Inc. | Apparatus and method for synchronizing dynamic process data across redundant input/output modules |
US9612587B2 (en) | 2014-02-11 | 2017-04-04 | Honeywell International Inc. | Mobile extension for industrial operator consoles |
US9720404B2 (en) | 2014-05-05 | 2017-08-01 | Honeywell International Inc. | Gateway offering logical model mapped to independent underlying networks |
US10042330B2 (en) | 2014-05-07 | 2018-08-07 | Honeywell International Inc. | Redundant process controllers for segregated supervisory and industrial control networks |
US9609524B2 (en) | 2014-05-30 | 2017-03-28 | Honeywell International Inc. | Apparatus and method for planning and validating a wireless network |
US10536526B2 (en) | 2014-06-25 | 2020-01-14 | Honeywell International Inc. | Apparatus and method for virtualizing a connection to a node in an industrial control and automation system |
US9699022B2 (en) | 2014-08-01 | 2017-07-04 | Honeywell International Inc. | System and method for controller redundancy and controller network redundancy with ethernet/IP I/O |
US10148485B2 (en) | 2014-09-03 | 2018-12-04 | Honeywell International Inc. | Apparatus and method for on-process migration of industrial control and automation system across disparate network types |
US10162827B2 (en) | 2015-04-08 | 2018-12-25 | Honeywell International Inc. | Method and system for distributed control system (DCS) process data cloning and migration through secured file system |
US10409270B2 (en) | 2015-04-09 | 2019-09-10 | Honeywell International Inc. | Methods for on-process migration from one type of process control device to different type of process control device |
US10296482B2 (en) | 2017-03-07 | 2019-05-21 | Honeywell International Inc. | System and method for flexible connection of redundant input-output modules or other devices |
CN116270632B (zh) * | 2023-01-18 | 2024-09-20 | 昆明市宇斯药业有限责任公司 | 一种脱毒雪上一枝蒿生物碱组合物及其制备方法 |
CN116942593B (zh) * | 2023-07-12 | 2024-03-29 | 广州中医药大学(广州中医药研究院) | 一种具有镇痛作用的微针及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0248526B2 (ja) * | 1980-02-26 | 1990-10-25 | Murayama Keikichi | Shinkinakoenshozai |
-
2004
- 2004-08-19 CN CNA2004100404834A patent/CN1621041A/zh active Pending
-
2005
- 2005-08-18 WO PCT/CN2005/001295 patent/WO2006017994A1/zh active Application Filing
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111991392A (zh) * | 2020-09-10 | 2020-11-27 | 青岛大学附属医院 | 一种抗疱疹病毒感染的生物碱及其组合物与应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2006017994A1 (fr) | 2006-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1621041A (zh) | 具有镇痛作用的药物组合物 | |
CN101031298B (zh) | 具有镇痛作用的药物 | |
CN1686458A (zh) | 一种中药组合物、其制备方法及其用途 | |
CN103083557A (zh) | 具有降血压和降血脂作用的中药组合物 | |
CN104983844A (zh) | 具有粘膜修复功能的组合物配方及其制剂的制备过程 | |
CN1316990C (zh) | 一种中药组合物及其制备方法和质量控制方法 | |
CN1806821A (zh) | 一种治疗鼻炎的药物 | |
CN102631526A (zh) | 一种用于治疗糖尿病的中药组合物 | |
CN1857622A (zh) | 包含天麻和川芎有效成分的药物组合物及制剂 | |
CN1876038A (zh) | 一种治疗胃腹疾病的中药组合物及其制备方法 | |
CN104000876A (zh) | 一种厚朴与姜辣素的组合物及其用途 | |
CN1179726C (zh) | 柚皮苷在制备支持性治疗非典型性肺炎药物中的应用 | |
CN1775263A (zh) | 杞菊地黄制剂及新的制备方法 | |
CN1775247A (zh) | 首乌地黄制剂及新的制备方法 | |
WO2011095095A1 (zh) | 一种含有醇溶性且非水溶性甘草提取物的药物组合物,及其药物制剂、制药用途、治疗方法和制备方法 | |
CN1968694B (zh) | 具有镇痛作用的药物组合物 | |
CN1824099A (zh) | 通宣理肺制剂及新的制备方法 | |
CN111714521B (zh) | 一种美洲大蠊肠道菌群代谢产物提取物及其制备方法和在制备抗炎或抗溃疡产品中的应用 | |
CN1742926A (zh) | 耳聋左慈制剂及新的制备方法 | |
CN1742854A (zh) | 槐角制剂及新的制备方法 | |
CN1823937A (zh) | 香连制剂及新的制备方法 | |
CN1282479C (zh) | 一种治疗口腔粘膜病的药物组合物及其制备方法 | |
CN102579453A (zh) | 一种治疗胃溃疡的复方制剂及其制备方法 | |
CN109806271B (zh) | 一种治疗过敏性皮炎的药物组合物及其制剂 | |
JP5389471B2 (ja) | 鼻閉抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: WANG JIANSHENG Free format text: FORMER OWNER: CHENGDU GIGI PHARMACEUTICAL CO., LTD Effective date: 20060714 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20060714 Address after: 610072, Sichuan, Chengdu, Qingjiang intersection, Vancouver square, 32 floor Applicant after: Wang Jiansheng Address before: 610072, Sichuan, Chengdu, Qingjiang intersection, Vancouver square, 32 floor Applicant before: Chengdu Zhizhi Pharmacy Group Co., Ltd. |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |